Epilepsy Drugs Industry: Global Market Size, Share, Growth, Opportunity and Forecast to 2021

MarketReportsOnline.com adds "Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021" research report to the pharmaceuticals segment of its online business intelligence and data library.

The research report titled "Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021" examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of epilepsy drugs industry sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for epilepsy drugs market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilepsy Drugs Market.

Company Coverage of Epilepsy Drugs Market: UCB, EISAI, Pfizer, Sanofi And Lundbeck

Complete report on Epilepsy Drugs market spread across 80 pages providing 5 company profiles with 6 tables and 23 figures is now available at http://www.marketreportsonline.com/577631.html.

Market growth can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.

Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.

Purchase a copy of this Epilepsy Drugs Market research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=577631.

The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market

Key Topics Covered in the Report
Worldwide Epilepsy Drugs Market Analysis (2013 - 2021)
Worldwide Epilepsy Drugs Market Share (2013 - 2021)
Worldwide Epilepsy Drugs Brand Market Performance (2013 - 2021)
Epilepsy Drugs Market - Major Deal Types
Key Companies Analysis
Key Drivers and Inhibitors of the Epilepsy Drugs Market

Key Epilepsy Drugs Covered in the Report are as follows: Vimpat (Lacosamide), Keppra (Levetiracetam), Briviact (Brivaracetam), Lamictal (Lamotrigine), Neurontin (Gabapentin), Depakine (Sodium Valproate), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa (Perampanel), Inovelon/Banzel (Rufinamide), Zonegran (Zonisamide), Zebinix (Eslicarbazepine Acetate)

Key Topics Covered:
1. Executive Summary
4. Key Drivers and Inhibitors of the Epilepsy Drugs Market
6. Epilepsy Drugs Market - Major Deal Types
7. Key Companies Analysis

Other Related Reports on Epilepsy Industry:
Global Epilepsy Market: Industry Analysis & Outlook (2017-2021): Epilepsy is a group of neurological diseases characterized by epileptic seizures. Epileptic seizures are episodes that can vary from brief and nearly undetectable to long periods of vigorous shaking. These episodes can result in physical injuries including occasionally broken bones. The medical definition of this disease is as a "condition characterized by recurrent (two or more) epileptic seizures, unprovoked by any immediate identified cause".

Global Epilepsy Partnering 2010 to 2017: The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

About Us:
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact Info:
Name: Ritesh Tiwari
Email: sales@marketreportsonline.com
Organization: MarketReportsOnline
Phone: +1 888 391 5441
Source URL: http://marketreportsonline.com/contacts/purchase.php?name=577631
Release ID: 179780

Contact Information
For more information visit http:// (http://)

Keywords

You can read this press release online here